Global Alzheimers Therapeutics Market Research Report 2018 | Now Available at Researchmoz.us

ResearchMoz presents professional and in-depth study of "Global Alzheimers Therapeutics Market Research Report 2018"
This report studies the global Alzheimers Therapeutics market status and forecast, categorizes the global Alzheimers Therapeutics market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa.

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.
Europe is estimated to grow at a rapid pace owing to the high prevalence of AD coupled with ever improving diagnostic capabilities. Asia Pacific is expected to witness the fastest growth over the forecast period owing to the rising disposable income level.

The global Alzheimers Therapeutics market is valued at xx million US$ in 2017 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2018-2025.

Get a Sample PDF at: https://www.researchmoz.us/enquiry.php?type=S&repid=1862860

The major manufacturers covered in this report
Pfizer, Inc.
Merck & Co. Inc.
Novartis AG
Eisai Co. Ltd.
H. Lundbeck A/S
AC Immune
TauRx Pharmaceuticals Ltd.
Actavis plc.
Forest Laboratories
Teva Pharmaceuticals Industries Ltd.
Janssen Pharmaceutical
GE healthcare
Eli Lilly And Company
DiaGenic ASA
VTV Therapeutics
Hoffman-La Roche Ltd.
AstraZeneca
Daiichi Sankyo Company Ltd.

Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering
North America
Europe
China
Japan
Southeast Asia
India

We can also provide the customized separate regional or country-level reports, for the following regions:
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Rest of Asia-Pacific
Europe
Germany
France
UK
Italy
Spain
Russia
Rest of Europe
Central & South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Saudi Arabia
Turkey
Rest of Middle East & Africa

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/global-alzheimers-therapeutics-market-research-report-2018-report.html/toc

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Donepezil
Memantine
Rivastigmine

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
Early to Moderate Stages
Moderate to Severe Stages

The study objectives of this report are:
To analyze and study the global Alzheimers Therapeutics sales, value, status (2013-2017) and forecast (2018-2025).
Focuses on the key Alzheimers Therapeutics manufacturers, to study the sales, value, market share and development plans in future.
Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
To define, describe and forecast the market by type, application and region.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends and factors driving or inhibiting the market growth.
To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Alzheimers Therapeutics are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025

Browse Detail Report @ https://www.researchmoz.us/global-alzheimers-therapeutics-market-research-report-2018-report.html

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders
Alzheimers Therapeutics Manufacturers
Alzheimers Therapeutics Distributors/Traders/Wholesalers
Alzheimers Therapeutics Subcomponent Manufacturers
Industry Association
Downstream Vendors

Asia-Pacific Alzheimers Therapeutics Awareness and Disease Modifying Therapies Markets 2021 | Latest Research Report

Researchmoz added Most up-to-date research on "Alzheimers Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies" to its huge collection of research reports.

Alzheimers Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first occur in patients in their mid-sixties, appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain. Mild Cognitive Impairment (MCI) is a heterogeneous condition between normal cognition and dementia, whereby cognitive changes in mental abilities, such as memory or thinking, are affected. Almost all cases of AD begin with MCI, but it should be noted that not all patients with MCI go on to develop AD.

Although there is a high degree of failure and uncertainty within the R&D of AD drugs, the number of drugs in the pipeline is considerable, at 559. The majority of the pipeline products are novel, and there are only seven repositioned drugs and five generic drugs. This shows progression in terms of the different molecules being developed as therapeutic agents within the AD pipeline.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=686320

Scope

The AD market has a lack of therapeutic options.
- Which classes of drug dominate the market?
- What newly approved therapies have entered the market?
- How do the leading marketed therapies compare clinically?
- How will the new therapies be positioned in the treatment of AD?
- How have selected late-stage pipeline therapies performed in clinical trials?

The pipeline contains a range of molecule types and molecular targets, including those that are well established in AD, and novel, first-in-class therapies.

- Which molecular targets appear most frequently in the pipeline?

AD clinical trials have an overall attrition rate of 94%.

- What are the failure rates for individual Phases of clinical development?
- How do AD clinical trial characteristics, including failure rate, duration, and size compare against respiratory and industry averages?

The AD market is forecast to rise from a value of $3 billion in 2014 to $5.1 billion in 2021, at a CAGR of 7.9% across the four Asia-Pacific markets assessed.

- How much of a role will disease prevalence and new product approvals play in market growth?
- Will generic competition have a significant impact on the market over the forecast period?

There have been 170 licensing deals and 104 co-development deals pertaining to AD products since 2006.

- Which territories show the most deal activity?
- What were the trends in deal completion by product stage of development?
- What were the conditions of the key licensing or co-development deals to take place in AD?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in AD.
- Assess the safety and efficacy of current treatment options, with extensive product profiles on prominent marketed therapies, and a heatmap directly comparing safety and efficacy data.
- Analyze the AD pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
- Predict growth in market size in four Asia-Pacific markets, with in-depth market forecasting from 2014 to 2021. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
- Identify commercial opportunities in the AD deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=686320